Month: February 2025
-
New MSD leader is one-of-a-kind
- 26 Feb 2025
Chifumi Umeda is a unique blend of Japanese and US cultures, finance and commercial skills, and she’s ready to deliver for Aust/NZ patients.
Read more -
Call for government intervention in radioligand stoush
- 26 Feb 2025
In response to Novartis’ legal action against local suppliers, this industry body says the Government must ‘act swiftly to ensure patients can access treatment’.
Read more -
Has the ‘politics of appeasement’ worked for pharma?
- 26 Feb 2025
OP-ED: Industry chose to push gently as GPs and pharmacists chose aggression. Is it time the medicines sector abandoned its ‘softly, softly’ approach?
Read more -
Commercial access head joins boutique firm
- 26 Feb 2025
With decades of experience in commercial and market access roles, Jo Atkins will now join Melbourne-based HEARS as a director and partner.
Read more -
Is Health running down the LSDP?
- 24 Feb 2025
Public investment in the Life Saving Drugs Program has declined significantly in recent years. Has it become too hard to get listed on the LSDP?
Read more -
AbbVie picks up market access Bridge
- 24 Feb 2025
After leading Bayer ANZ’s access team for nearly five years, Sarah Bridge has made the move to AbbVie as Novartis loses medical exec.
Read more -
Medtronic moving to lush new office
- 24 Feb 2025
While pharma companies leave Pill Hill for the bright city lights, the medical devices sector is continuing to invest in Macquarie Park.
Read more -
New look, new office for RCA
- 24 Feb 2025
Rare Cancers Australia undergoes brand refresh with a new website, office and logo representing ‘work we’re doing today and into the future’.
Read more








